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Figure 1 Chemical structure
186 Md. Faiyazuddin et al.from 6.31 to 9.13 h at 20 C. Frozen at 20 C, this drug was stable for at least 2 months (without
losses >10%). The maximum plasma concentration (Cpmax) was found to be 5875.03 ±
114 ng mL1, which is signiﬁcantly higher than the maximum saliva concentration (Csmax,
1501.69 ± 96 ng mL1). Therefore, the validated method could be used to carry out pharmacoki-
netic studies of the TBS from novel drug delivery systems.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Asthma is one of the most frequent diseases inﬂuencing the hu-
man pursuit, with 610% of the adult population suffering
from asthma or related conditions (Bhavna et al., 2009). Asth-
ma has a diurnal rhythm and in most of the patients, pulmon-
ary function gets reduced from midnight sustained up to 8 h.
Thus a perfect therapeutic agent should have effective
measures in preventing bronchospasm for the period of 6–
8 h during which most individuals sleep. Terbutaline sulfate;
b-[(tert-butylamino) methyl]-3,5-dihydroxy-benzyl alcohol
(C12H19NO3) (TBS; Fig. 1) is a synthetic b2-adrenoceptor
(b2AR) agonist that is widely used as a bronchodilator in acute
and long-term treatment of bronchial asthma, chronic bron-
chitis and emphysema and other chronic obstructive pulmon-
ary diseases (COPD) with reversible bronchial hyper-reactive
conditions (Borgstro¨m et al., 1989; Daraghmeh et al., 2002).
TBS is a selective b2 adrenoceptor agonist. TBS is a short-act-
ing bronchodilator which can be administered orally, parenter-
ally or by suitable inhalation systems (DPI or nebulization).
Orally administered terbutaline is absorbed incompletely.
TBS undergoes high ﬁrst-pass metabolism in the gut-wall
and liver and limits bioavailability up to 15% (Daraghmeh
et al., 2002). Peak plasma levels are 1.2 lg mL1 for every
mg of an oral dose, reached within 2–3 h. Following inhala-
tion, only about 10–20% of inhaled dose reaches the lungs
but after nanosizing the drug candidate >50% can be targeted
deeper to alveolar region (Bhavna et al., 2009). Several analyt-
ical techniques like, ultraviolet spectroscopy (Selek et al., 2003;
Shahin et al., 2002), voltammetery (Beltagi et al., 2007), capil-
lary electrophoresis (Boer and Ensing, 1998; Kim et al., 2000),
chemiluminescence (Li et al., 2009), high performance liquid
chromatography (Chiap et al., 2002; Herring and Johnson,
2000; Jacobson and Peterson, 1994; Reverchon and Porta,
2003; Sagar et al., 1993), LC-electrochemical detection
(Edholm et al., 1984; Zhang and Zhang, 2004), LC–tandem
MS (Dickson et al., 2005; Fesser et al., 2005), GC–MS (Spisso
et al., 2000), and electrospray high-ﬁeld asymmetric waveform
ion mobility spectrometry–mass spectrometry (ESI-FAIMS–of terbutaline sulfate.MS) (Mie et al., 2008) have been reported in the literature
for quantiﬁcation of TBS; but most of them either employ
large sample volumes or have long extraction processes. For
pharmacokinetic studies, the most useful bioanalytical method
reported is GC–MS (Borgstro¨m et al., 1989; Spisso et al., 2000;
Bredberg et al., 1992). Isolation of unchanged compounds and
metabolites from biological samples by GC–MS necessitates
elimination of matrix interferences by liquid–liquid extraction
(Henze et al., 2001), solid phase extraction or both (Black and
Hansson, 1999; Couper and Drummer, 1996). Owing to its po-
tency, TBS is employed in very mere quantities and its determi-
nation in biological ﬂuids requires the detection of nanogram
or subnanogram/mL levels (Damasceno et al., 2000). Although
the above methods were found promising for the determina-
tion of TBS in bio-ﬂuids but high expertise need limits routine
analysis. In order to circumvent above mentioned problems,
we adopted our previously validated stability indicating high
performance thin layer chromatographic method (Faiyazuddin
et al., 2010), which was capable of evaluating TBS concentra-
tions in saliva and plasma with a single step extraction with
methanol. The method was validated with respect to accuracy,
precision, robustness, selectivity and limit of quantiﬁcation
and limit of detection according to FDA guidelines (FDA,
2001).2. Materials and methods
2.1. Materials
Terbutaline sulfate (Assigned purity >98.54%) was received
as gift sample from Netco Limited, Hyderabad, India. All
chemicals and reagents used were of analytical grade and were
purchased from E. Merck (Mumbai, India). Plasma was re-
ceived from Yash Pharma Laboratories, Mumbai, India. For
validation of method, biological samples were collected from
volunteers (Hamdard University, New Delhi) and processed.2.2. Methodology
2.2.1. Chromatography
TheHPTLC analysis was performed on precoated silica gel alu-
minum plate 60F254 (20 cm · 10 cm, 200 lm thickness,
E. Merck, Germany) as a stationary phase for TBS
(Faiyazuddin et al., 2010). The samples were spotted as bands
of width 6 mm wide and 10 mm apart by means of CAMAG
syringe using aLinomatV (CAMAG, Switzerland) sample appli-
cator. The equipment parameters include constant application
rate of 160 nL s1, slit dimension of 5 mm · 0.45 mm and scan-
ning speed of 20 mm s1. The mobile phase consisted of chloro-
form–methanol (9.0:1.0, v/v). Densitometric scanning was
performed on a CAMAG TLC scanner III in ﬂorescent mode
at 366 nm and operated by win CATS software (Version 1.2.0).
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samples of plasma and saliva
A stock solution was prepared by dissolving 100 mg of TBS in
10 mL of methanol. Working solutions ranging from 1 to
10 mg mL1 were prepared by properly diluting the stock solu-
tion with methanol. Ten microliters of each working solution
of TBS were used to spike plasma and saliva samples (1 mL)
in order to obtain calibration standards ranging from 10 to
100 lg mL1. QC samples were prepared at concentrations
of 20, 60 and 80 lg mL1.
2.2.3. Sample preparation
Previous to analysis, plasma and saliva samples were thawed at
room temperature (RTP) for about 10 min and 1 mL of plas-
ma and saliva calibration standards and QC samples were
transferred into small eppendorf tubes and mixed with 1 mL
of methanol. After vigorous vortexing for 1 min, the samples
were centrifuged (5 min;>2000g). Then supernatant was trans-
ferred to glass microvials and the solvent was evaporated
(<50 C). The plasma and saliva samples were reconstituted
with 100 lL of methanol. One microliter of each sample was
spotted on the TLC plate to obtain the ﬁnal calibration range
of 100–1000 ng spot1. QC samples at ﬁnal concentration of
200, 600 and 800 ng spot1 were obtained after spotting. Each
concentration was spotted six times on the TLC plate.
2.2.4. Bioanalytical method validation
The method was validated for speciﬁcity, precision, accuracy,
sensitivity, recovery and robustness according to the USFDA
guidelines for validation of bioanalytical methods (FDA, 2001).
2.2.4.1. Speciﬁcity. The speciﬁcity was investigated by screen-
ing three different batches of blank plasma and saliva samples.
All the samples were cleaned up as described in Section 2.2.3.
The RF values of endogenous compounds in the matrices were
compared with those of TBS.
2.2.4.2. Precision and accuracy. Precision and accuracy were
evaluated by performing replicate analyses of QC samples at
three levels (200, 600 and 800 ng spot1) in plasma and saliva.
Intra-day repeatability was determined by treating spiked sam-
ples in six replicates on the same day. Inter-day repeatability
was studied by comparing the results of assays performed on
different days on the same spiked samples, also in six replicates
for each kind of sample. The reproducibility of the method was
checked by determining precision on a different instrument.
The precision was expressed in terms of percentage coefﬁcient
of variation (CV, %), whereas accuracy was expressed as per-
cent recovery.
2.2.4.3. Robustness. Robustness studies were done in triplicate
at a concentration level of 600 ng spot1. Chloroform–metha-
nol (9.0:1.0, v/v) (9.0 ± 0.5:1.0 ± 0.5) were tried to assess
robustness of the method. The amounts of mobile phase and
durations of saturation were varied at 20 ± 2 mL and
30 ± 10 min, respectively. The time from spotting to chroma-
tography and from chromatography to scanning was varied
from 0, 10 and 20 min. The effects on the results were ex-
pressed as standard deviations.
2.2.4.4. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ). In order to determine LOD and LOQ each of blankplasma and saliva samples were spotted six times on TLC plate
and the standard deviations (r) of the magnitude of analytical
response were determined. The LOD was expressed as 3.3r/
slope, whereas LOQ was expressed as 10r/slope of the calibra-
tion curve of the TBS.
2.2.4.5. Recovery studies. Extraction efﬁciency or recovery was
determined for TBS in triplicate at 200, 600 and 800 ng spot1
in all matrices. The peak areas obtained after extraction were
compared with peak areas resulting from standard solutions
at the same concentrations.
2.2.5. Ex vivo stability
2.2.5.1. Long term stability. For the purpose of stability con-
cern, three different concentrations of QC samples were used.
After spiking in plasma and saliva, aliquots were stored at 4
and 20 C. The stability was assessed after 0.5, 1, 2, 4 and
8 h. The stability of the drug in frozen samples (20 C)
was determined by periodic analysis over a period of
2 months. Previous to analysis, biological samples were
brought to room temperature and extraction was performed.
Degradation rate constant (Kobs), half-life (T0.5) and shelf life
(T0.9) of TBS in plasma and saliva were also obtained at 4
and 20 C.
2.2.5.2. Freeze thaw stability. In favor of freeze thaw stability
studies, 9 aliquots of each QC sample (in each matrix) were
stored at 20 C for 24 h; then they were left to completely
thaw at room temperature. Three aliquots of each QC sample
were analyzed after extraction and rest of the aliquots were re-
turned to 20 C for another 24 h. The cycle was repeated
three times.
2.2.5.3. Short term stability. Stability of TBS in methanol
(stock solution) was assessed at 4 and 20 C. Run time stability
at room temperature of processed samples after extraction was
determined for QC samples. To test the stability, samples were
analyzed immediately after preparation (control) and after a
stipulated time period.
2.2.6. Pharmacokinetic study
In order to authenticate the applicability of proposed method,
the pharmacokinetic study with marketed TBS tablet prepara-
tion was performed in three healthy volunteers after a single
oral dose (5 mg). The blood and saliva samples were collected
at 1.0, 2.0, 4.0, 8.0, 12.0 and 24.0 h after dosing. All blood sam-
ples were collected in heparinized tubes and plasma was pro-
cured after centrifugation (1000g; 20 min). All the samples
were frozen at 20 C until analysis.3. Results and discussion
3.1. Calibration curves
The linear regression data for the calibration curves in plasma
and saliva are shown in Table 1. TBS was well resolved at RF
0.34. The peak area vs. concentration ﬁtted well to a straight
line, with the following equations: Y= (4.638 ± 0.033)X+
(1255.23 ± 14.95) and Y= (3.722 ± 0.019)X+ (978.65 ±
10.13) in plasma and saliva, respectively. The correlation coef-
ﬁcients (r2) for calibration curves were equal to or better than
Table 1 Linear regression data for the calibration curves
(n= 6).
Parameter Value
Plasma Saliva
Linearity range (ng spot1) 100–1000 100–1000
Correlation coeﬃcient
(r2 ± SD)
0.9982 ± 0.0015 0.9943 ± 0.0018
Slope
Mean ± SD 4.638 ± 0.033 3.722 ± 0.019
Conﬁdence limita 4.597–4.682 3.698–3.746
Standard error 0.013 0.008
Intercept
Mean ± SD 1255.23 ± 14.95 978.65 ± 10.13
Conﬁdence limita 1236.25–1272.18 966.56–990.11
Standard error 6.103 4.135
a 95% conﬁdence limit.
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3.2. Bioanalytical method validation
3.2.1. Speciﬁcity
Chromatograms of TBS (drug) free plasma and saliva samples
are represented in Figs. 2(a) and 3(a) respectively. Plasma and
saliva samples spiked at concentration of 600 ng spot–1 are
shown in Figs. 2(b) and 3(b) respectively. As exposed in both
ﬁgures (Figs. 2 and 3; RF: 0.34), TBS eluted was free of inter-
ferences in all of the drug free plasma and saliva samples.
3.2.2. Precision and accuracy
The intra and inter-day precision and accuracy of the assay are
described in Table 2. The intra-day precision was 62.86% and
4.37% in plasma and saliva, respectively. The values for inter-
day precision were 64.37% and 5.19% in plasma and saliva,
respectively. The intra and inter-day accuracy calculated as
percent recovery, ranged 96.77–99.15% for the matrices stud-
ied. The low values of CV (<5.19%), with no signiﬁcant dif-
ferences between values for intra and inter-day precision,
indicate the method’s reproducibility.Figure 2 Chromatograms of (a) drug-free plasma and (b) plasma
conditions: mobile phase, chloroform–methanol (9.0:1.0, v/v); UV det3.2.3. Robustness
Table 3 summarizes the average values of SD, SE and % RSD
of the peak areas for each parameter at a concentration level of
600 ng spot1 in plasma and saliva samples. The low values of
SE (62.52) and % RSD (61.12) obtained after introducing
small deliberate changes in the developed method indicated
the robustness of the HPTLC method.
3.2.4. LOD and LOQ
The LOD and LOQ of TBS were found to be 7.41 and
18.35 ng spot1, respectively. The low LOD and LOQ values
indicate the adequate sensitivity of the proposed method.
3.2.5. Extraction recovery
In plasma, the mean recovery (n= 6) averaged 95.92 ± 4.41%
for TBS, however in saliva (n= 6) the recovery was
98.35 ± 2.72%. The extraction efﬁciency is not statistically
different over the range of concentration studied.
3.3. Ex vivo stability
The stability of TBS was investigated in plasma and saliva
samples. Each experiment was performed in triplicate and
the mean concentration of TBS was calculated. A monoexpo-
nential decline in drug (TBS) concentration was observed at
both 4 and 20 C, in all biomatrices studied. After storage at
20 C for 8 h; the drug degradation was substantial and the
percentage recovery of TBS decreases to 40.2 ± 2.58% and
58.5 ± 4.75% of the initial concentrations in plasma and sali-
va, respectively. In contrast, higher recovery of TBS in plasma
(55.8 ± 7.12%) and saliva (68.2 ± 3.19%) was obtained after
storage at 4 C for 8 h. The degradation rate constant (Kobs) of
TBS in plasma and saliva were 0.11, 0.076 h1, respectively at
20 C, indicating that the drug was least stable in plasma
(Fig. 4). Moreover, half-life (T0.5) and shelf life (T0.9) of drug
in plasma, and saliva were obtained from the slope of the
straight lines at both temperatures. The corresponding half-life
values ranged from 6.31 to 9.13 h at 20 C and from 9.92 to
12.41 h at 4 C. The long term freezer stability (20 C) indi-
cated that TBS was stable in the studied matrices during
2 months. The percent recovery averaged 94.35%. The freeze
thaw data indicate that, as a minimum, two freeze thaw cycles
can be tolerated without losses higher than 10%. Stockspiked at a concentration of 600 ng spot1. Chromatographic
ection at 366 nm; TBS peak RF 0.34 ± 0.02.
Table 2 Precision and accuracy of HPTLC method for TBS.
Actual concentration
(ng spot1)
Intra-day reproducibility Inter-day reproducibility
Concentration found
(ng spot1) (mean ± SD)
Precisiona
(CV; %)
Accuracyb
(%)
Concentration
found (ng spot1)
(mean ± SD)
Precisiona
(CV; %)
Accuracyb
(%)
Plasmac
200 194.32 ± 5.57 2.86 97.16 193.54 ± 8.46 4.37 96.77
600 593.25 ± 8.42 1.41 98.87 591.28 ± 11.72 1.98 98.54
800 788.89 ± 14.68 1.86 98.61 790.64 ± 13.55 1.71 98.83
Salivac
200 195.16 ± 9.11 4.66 97.58 197.12 ± 10.24 5.19 97.40
600 592.27 ± 11.45 1.93 98.71 594.72 ± 12.64 2.12 99.12
800 791.35 ± 12.53 1.58 98.91 793.25 ± 13.72 1.72 99.15
a Precision as coefﬁcient of variation (CV; %) = SD/mean concentration · 100.
b Accuracy = mean concentration/nominal concentration · 100.
c Mean of six determinations (n= 6).
Figure 3 Chromatograms of (a) drug-free saliva and (b) saliva spiked at a concentration of 600 ng spot1. Chromatographic conditions:
mobile phase, chloroform–methanol (9.0:1.0, v/v); UV detection at 366 nm; TBS peak RF 0.34 ± 0.02.
Table 3 Robustness of the HPTLC method (na = 3; 600 ng spot1).
Parameter SDb (peak area) SEb % RSD
Mobile phase composition: chloroform–methanol (9.0 ± 0.5:1.0 ± 0.5, v/v) 3.53 2.03 1.06
Mobile phase volume (18, 20 and 22 mL) 4.38 2.52 1.12
Duration of saturation (20, 30 and 40 min) 2.76 1.59 0.96
Time from spotting to chromatography (0, 10 and 20 min) 3.62 2.09 1.11
Time from chromatography to scanning (0, 10 and 20 min) 2.57 1.48 0.84
a Mean of three determinations (n= 3).
b Average of results obtained from plasma and saliva.
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at 4 C without measurable degradation. Stability at room
temperature of processed samples after extraction was deter-
mined. After 12 h no signiﬁcant losses occurred.
3.4. Pharmacokinetic study
The method was used for analysis of plasma and saliva sam-
ples obtained after oral administration of single TBS (5 mg).Fig. 4 shows the mean concentration–time proﬁles for TBS.
The maximum plasma concentration (Cpmax) was found to
be 5875.03 ± 114 ng mL1, which is signiﬁcantly higher than
the maximum saliva concentration (Csmax, 1501.69 ± 96
ng mL1). The result indicates that higher plasma levels were
obtained after oral administration of TBS. Experimental
Cpmax values after oral administration were comparable with
reported data indicating that this method is suitable for phar-
macokinetic studies.
Figure 4 Concentration–time proﬁle for TBS in the plasma and
saliva samples (oral administration: 5 mg tablet).
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This is the foremost validated HPTLC method for determina-
tion of TBS in plasma and saliva samples. Under the described
conditions, the RF 0.34; where TBS eluted, was free of interfer-
ences in all of the drug free plasma and saliva investigated. UV
spectra measured on the spots showed maximal absorbance at
about 366 nm; improved detection sensitivity, speciﬁcity and
minimized interferences from biological ﬂuids that may occur
at lower wavelengths. The methanol used to elute the plasma
samples enables rapid extraction with few impurities and no
interfering substances. The present method is also used to
study the stability of TBS in plasma and saliva. The results
indicate that the rapid degradation of drug occurred in both
matrices and that the half-life of the drug ranged from 9.92
to 12.41 h at 4 C and from 6.31 to 9.13 h at 20 C. However,
there was no signiﬁcant degradation of the compound follow-
ing extraction with methanol. We observed that stock solu-
tions of TBS in methanol were stable for 2 days at 20 C and
for 6 days at 4 C without measurable degradation. The meth-
od described is a sensitive and speciﬁc assay for TBS in bioma-
trices and is suitable for pharmacokinetic studies after
therapeutic doses.
Ex vivo stability and pharmacokinetic investigations were
carried out for TBS in plasma and saliva samples by validated
HPTLC method. As the method has low detection limits, high
recovery rate and good reproducibility in biomatrices; there-
fore it can be employed for routine analysis. HPTLC method
is user-friendly technique and our developed method is per-
haps the ﬁrst HPTLC method for TBS; hence in future it
can be used to study the degradation mechanism of TBS in
the form of its metabolites. The method could be used to carry
out pharmacokinetic studies of the TBS from novel drug deliv-
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